Clinical trial
A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia
NCT00400673 · Northern Italy Leukemia Group, Other · Completed
Key facts
| NCT number | NCT00400673 |
|---|---|
| Title | A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia |
| Official title | Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia |
| Lead sponsor | Northern Italy Leukemia Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Behavioral |
| Interventions | Two-step remission induction and risk-oriented consolidation |
| Enrollment | 581 |
| Start date | May 1, 2000 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Nov 17, 2006 |
| Last update posted | Apr 1, 2011 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: